Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS Initial data from the dose escalation phase using a July 15, 2024 data cutoff date indicate that ...

allowing for control of tumors in vivo without the need for exogenous or engineered cytokines – – Posters include demonstration of advances in gene editing and transgene design that enable ...

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and ...

– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development ...

"We look forward to the presentation of posters at ASH from across our product portfolio. We are very encouraged by the preliminary safety and efficacy data from our ongoing Phase 1b study of R289 ...

allowing for control of tumors in vivo without the need for exogenous or engineered cytokines- - Posters include demonstration of advances in gene editing and transgene design that enable greater ...

today announced that the company will present two oral presentations and one poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting, being held December 7-10, 2024, in San ...

Taking a jibe at UP CM’s recent “batenge toh katenge” remark, the SP has put up banners with the slogan – ‘Na Katenge, Na Batenge’ ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

A national Muslim advocacy group says Montreal would send the wrong message if it takes down a welcome sign in the lobby at ...